{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:30:35Z","timestamp":1740130235053,"version":"3.37.3"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_19059"],"award-info":[{"award-number":["MC_PC_19059"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edinburgh Clinical Academic Track (ECAT)\/Wellcome Trust PhD Training Fellowship for Clinicians","award":["214178\/Z\/18\/Z"],"award-info":[{"award-number":["214178\/Z\/18\/Z"]}]},{"name":"BBSRC funding at The Roslin Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Successful host defence against infectious disease involves resistance (reduce pathogen load) and tolerance (reduce tissue damage associated with pathogen presence). Integration of clinical, immunologic, genetic and therapeutic discoveries has identified defects in both of these responses in the progression from SARS-CoV-2 infection to life-threatening coronavirus disease 2019 (Covid-19) lung injury. Early after infection with SARS-CoV-2, resistance can be compromised by a failed type 1 interferon (IFN-I) response, due to direct viral antagonism of induction and signalling, deleterious host genetic variants (IFNAR2, IFNA10, TYK2 and PLSCR1), and neutralizing auto-antibodies directed against IFN-I (predominantly IFN-\u03b1). Later in the disease, after pathogen sensing has activated a pro-inflammatory response, a failure to appropriately regulate this response compromises tolerance resulting in virus-independent immunopathology involving the lung and reticuloendothelial system. Monocytes are activated in the periphery (involving M-CSF, GM-CSF, IL-6, NLRP1 inflammasomes, TYK2 and afucosylated anti-spike IgG) then recruited to the lung (involving CCR2::MCP-3\/MCP-1 and C5a::C5aR1 axes) as pro-inflammatory monocyte-derived macrophages, resulting in inflammatory lung injury. Phenotypic and genotypic heterogeneity is apparent in all these responses, identifying \u2018treatable traits\u2019 (therapeutically relevant components of inter-individual variation) which could be exploited to achieve a stratified medicine approach to Covid-19. Overall, Covid-19 pathogenesis re-affirms the importance of resistance in surviving an infectious disease and highlights that tolerance is also a central pillar of host defence in humans and can be beneficially modified using host-directed therapies.<\/jats:p>","DOI":"10.1093\/qjmed\/hcac143","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:06:06Z","timestamp":1654866366000},"page":"513-519","source":"Crossref","is-referenced-by-count":1,"title":["Defining resistance and tolerance traits in Covid-19: towards a stratified medicine approach"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-8243","authenticated-orcid":false,"given":"C D","family":"Russell","sequence":"first","affiliation":[{"name":"Queen\u2019s Medical Research Institute, University of Edinburgh Centre for Inflammation Research , Edinburgh BioQuarter, 47 Little France Crescent , Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Clohisey Hendry","sequence":"additional","affiliation":[{"name":"Division of Genetics and Genomics, Roslin Institute, University of Edinburgh, Easter Bush Campus , Midlothian EH25 9RG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2022081316575110300_hcac143-B1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1126\/science.1214935","article-title":"Disease tolerance as a defense strategy","volume":"335","author":"Medzhitov","year":"2012","journal-title":"Science"},{"key":"2022081316575110300_hcac143-B2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-2600(21)00175-2","article-title":"Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO clinical characterisation protocol UK","volume":"9","author":"Docherty","year":"2021","journal-title":"Lancet Respir Med"},{"year":"2022","author":"Millar","key":"2022081316575110300_hcac143-B3"},{"key":"2022081316575110300_hcac143-B4","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg9873","article-title":"Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19","volume":"6","author":"Thwaites","year":"2021","journal-title":"Sci Immunol"},{"key":"2022081316575110300_hcac143-B5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in COVID-19","volume":"591","author":"Pairo-Castineira","year":"2021","journal-title":"Nature"},{"key":"2022081316575110300_hcac143-B6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.coisb.2017.04.003","article-title":"Treatable traits and therapeutic targets: goals for systems biology in infectious disease","volume":"2","author":"Russell","year":"2017","journal-title":"Curr Opin Syst Biol"},{"key":"2022081316575110300_hcac143-B7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","article-title":"Tissue-specific immunopathology in fatal COVID-19","volume":"203","author":"Dorward","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2022081316575110300_hcac143-B8","doi-asserted-by":"crossref","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of type I interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep"},{"key":"2022081316575110300_hcac143-B9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022081316575110300_hcac143-B10","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat Commun"},{"key":"2022081316575110300_hcac143-B11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat Immunol"},{"year":"2021","author":"Hatton","key":"2022081316575110300_hcac143-B12"},{"key":"2022081316575110300_hcac143-B13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"2022081316575110300_hcac143-B14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Trouillet-Assant","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2022081316575110300_hcac143-B15","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"2022081316575110300_hcac143-B16","article-title":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs","volume":"218","author":"Lopez","year":"2021","journal-title":"J Exp Med"},{"key":"2022081316575110300_hcac143-B17","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04576-6","article-title":"Whole genome sequencing reveals host factors underlying critical Covid-19","author":"Kousathanas","year":"2022","journal-title":"Nature"},{"key":"2022081316575110300_hcac143-B18","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"11","author":"Fajnzylber","year":"2020","journal-title":"Nat Commun"},{"key":"2022081316575110300_hcac143-B19","doi-asserted-by":"crossref","first-page":"e0258421","DOI":"10.1371\/journal.pone.0258421","article-title":"SARS-CoV-2 viral load as a predictor for disease severity in outpatients and hospitalised patients with COVID-19: a prospective cohort study","volume":"16","author":"Knudtzen","year":"2021","journal-title":"PLoS One"},{"key":"2022081316575110300_hcac143-B20","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2213-2600(20)30354-4","article-title":"SARS-CoV-2 viral load predicts COVID-19 mortality","volume":"8","author":"Pujadas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2022081316575110300_hcac143-B21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"2022081316575110300_hcac143-B22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"2022081316575110300_hcac143-B23","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2666-5247(20)30115-4","article-title":"Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study","volume":"1","author":"Hanley","year":"2020","journal-title":"Lancet Microbe"},{"key":"2022081316575110300_hcac143-B24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60361","article-title":"Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage","volume":"10","author":"Deinhardt-Emmer","year":"2021","journal-title":"Elife"},{"key":"2022081316575110300_hcac143-B25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-021-03475-6","article-title":"The spatial landscape of lung pathology during COVID-19 progression","volume":"593","author":"Rendeiro","year":"2021","journal-title":"Nature"},{"key":"2022081316575110300_hcac143-B26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03569-1","article-title":"A molecular single-cell lung atlas of lethal COVID-19","volume":"595","author":"Melms","year":"2021","journal-title":"Nature"},{"key":"2022081316575110300_hcac143-B27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41591-021-01329-2","article-title":"Single-cell multi-omics analysis of the immune response in COVID-19","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat Med"},{"key":"2022081316575110300_hcac143-B28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"key":"2022081316575110300_hcac143-B29","article-title":"A humanized mouse model of chronic COVID-19","author":"Sefik","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2022081316575110300_hcac143-B30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.12688\/wellcomeopenres.16584.2","article-title":"A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS","volume":"6","author":"Reyes","year":"2021","journal-title":"Wellcome Open Res"},{"key":"2022081316575110300_hcac143-B31","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"Veras","year":"2020","journal-title":"J Exp Med"},{"key":"2022081316575110300_hcac143-B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4049\/jimmunol.1500369","article-title":"Specific contributions of CSF-1 and GM-CSF to the dynamics of the mononuclear phagocyte system","volume":"195","author":"Louis","year":"2015","journal-title":"J Immunol"},{"key":"2022081316575110300_hcac143-B33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-020-58131-2","article-title":"Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes","volume":"10","author":"Lotfi","year":"2020","journal-title":"Sci Rep"},{"key":"2022081316575110300_hcac143-B34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"2022081316575110300_hcac143-B35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1165\/rcmb.2021-0358OC","article-title":"Tissue proteomic analysis identifies mechanisms and stages of immunopathology in fatal COVID-19","volume":"66","author":"Russell","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2022081316575110300_hcac143-B36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nchembio.2229","article-title":"DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis","volume":"13","author":"Okondo","year":"2017","journal-title":"Nat Chem Biol"},{"key":"2022081316575110300_hcac143-B37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41418-020-00621-x","article-title":"TYK2 licenses non-canonical inflammasome activation during endotoxemia","volume":"28","author":"Poelzl","year":"2021","journal-title":"Cell Death Differ"},{"key":"2022081316575110300_hcac143-B38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2022081316575110300_hcac143-B39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"2022081316575110300_hcac143-B40","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8378","article-title":"Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity","volume":"371","author":"Larsen","year":"2021","journal-title":"Science"},{"key":"2022081316575110300_hcac143-B41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41590-020-00828-7","article-title":"Proinflammatory IgG Fc structures in patients with severe COVID-19","volume":"22","author":"Chakraborty","year":"2021","journal-title":"Nat Immunol"},{"key":"2022081316575110300_hcac143-B42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8654","article-title":"High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages","volume":"13","author":"Hoepel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022081316575110300_hcac143-B43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081316575110300_hcac143-B44","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022081316575110300_hcac143-B45","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","article-title":"Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"Nat Commun"},{"key":"2022081316575110300_hcac143-B46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022081316575110300_hcac143-B47","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/art.23591","article-title":"Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial","volume":"58","author":"Vergunst","year":"2008","journal-title":"Arthritis Rheum"},{"year":"2021","author":"Patel","key":"2022081316575110300_hcac143-B48"},{"key":"2022081316575110300_hcac143-B49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"year":"2022","author":"Horby","key":"2022081316575110300_hcac143-B50"},{"key":"2022081316575110300_hcac143-B51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41590-020-00826-9","article-title":"Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum","volume":"22","author":"Weisberg","year":"2021","journal-title":"Nat Immunol"},{"key":"2022081316575110300_hcac143-B52","article-title":"Fostamatinib for the treatment of hospitalized adults with COVID-19\u2014a randomized trial","author":"Strich","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcac143\/44145604\/hcac143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/115\/8\/513\/45416501\/hcac143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/115\/8\/513\/45416501\/hcac143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T16:58:44Z","timestamp":1660409924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/115\/8\/513\/6605227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,10]]},"published-print":{"date-parts":[[2022,8,13]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcac143","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"type":"print","value":"1460-2725"},{"type":"electronic","value":"1460-2393"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,10]]}}}